IP InterviewPublished July 29, 2024
Danaher: Cytiva & the Chromatography Process
inpractise.com/articles/danaher-cytiva-pharmacia-and-the-chromatography-process
Executive Bio
Former Head of Sales, GE Life Sciences
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
What would you be worried about if you were running Cytiva over next 10 years?
I would be worried about future developments within genetic engineering. I'm sure there will be some minor effects. The problem is that, you know, GE Amersham, or whatever we call it, we worked with that. We have the technology to produce genetic material on a large scale, but there are very few successes.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content
Thermo Fisher Scientific Inc: Culture and Management
Former Director at Thermo Fisher Scientific
Danaher, Aldevron, Intangible & Goodwill Impairments
Porvair & Chromatography Lab Equipment: M&A Process & Culture
Former Senior Vice President Life Sciences at J.G. Finneran, Porvair plc
Thermo Fisher vs Danaher: Business Model and Competitive Positioning
Former Director, Corporate Strategy & Business Development at Thermo Fisher Scientific
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.